Novartis (NYSE:NVS) shares are in the green in the pre-markets session today after two phase 3 clinical trials showed its Consentyx demonstrated superior efficacy over placebo in symptoms of skin disease hidradenitis suppurativa (HS).
HS affects about one in 100 people globally causing painful lesions. The company has submitted data from the two trials to European authorities and plans to submit it in the U.S. by the end of the year as well.
The drug showed rapid relief from the ailment as well as a favorable safety profile. Long-term results from these trials are expected in 2023. Additionally, Novartis also aims to expand the drug to 10 indications.
Read full Disclosure
